Effect of s-LCA on hematologic recovery and clinical outcomes
| Clinical outcome . | s-LCA negative5-150 (N = 15) . | s-LCA positive5-150 (N = 8) . | P5-153 . |
|---|---|---|---|
| Hematologic recovery | |||
| Variables | |||
| CD34 dose (×106/kg) | 3.0 (2.0-5.5) | 3.8 (1.4-13.1) | 0.44 |
| Prior chemotherapy regimens | 1.9 (1-3) | 1.9 (1-2) | 0.76 |
| Prior chemotherapy cycles | 8.8 (3-16) | 8.2 (2-15) | 0.76 |
| Days G-CSF | 14.2 (11-18) | 17.0 (12-30) | 0.10 |
| Neutrophil recovery | |||
| Days to ANC | |||
| >500/μL | 10.8 (9-18) | 12.0 (10-15) | 0.18 |
| >1000/μL | 12.1 (10-18) | 17.8 (10-36) | 0.03 |
| >1500/μL | 12.6 (10-18) | 19.8 (12-36) | 0.01 |
| Platelet recovery | |||
| Days to PLTS | |||
| >20 000/μL | 24.0 (9-67) | 32.0 (15-85) | 0.38 |
| >50 000/μL | 29.3 (14-49) | 34.4 (27-43) | 0.40 |
| Clinical outcomes | |||
| Febrile days | |||
| Days 2 to 10 | 4.1 (0-6) | 6.3 (5-8) | 0.01 |
| Start of regimen to day 1 | 0.2 (0-2) | 0.5 (0-4) | 0.47 |
| Days IV antibiotics | |||
| Day 2 to neutrophil engraftment5-151 | 7.3 (0-11) | 10.5 (8-13) | 0.01 |
| Start of regimen to day 1 | 0.5 (0-3) | 1.0 (0-4) | 0.40 |
| Days amphotericin B | 0 (0-0) | 1.3 (0-5) | 0.02 |
| Platelet transfusions | |||
| Day 2 to platelet engraftment5-152 | 3.4 (0-10) | 7.6 (1-18) | 0.05 |
| Start of regimen to day +1 | 0 | 0 | — |
| Days 2 to 10 | 2.1 (0-5) | 2.6 (1-7) | 0.46 |
| Clinical outcome . | s-LCA negative5-150 (N = 15) . | s-LCA positive5-150 (N = 8) . | P5-153 . |
|---|---|---|---|
| Hematologic recovery | |||
| Variables | |||
| CD34 dose (×106/kg) | 3.0 (2.0-5.5) | 3.8 (1.4-13.1) | 0.44 |
| Prior chemotherapy regimens | 1.9 (1-3) | 1.9 (1-2) | 0.76 |
| Prior chemotherapy cycles | 8.8 (3-16) | 8.2 (2-15) | 0.76 |
| Days G-CSF | 14.2 (11-18) | 17.0 (12-30) | 0.10 |
| Neutrophil recovery | |||
| Days to ANC | |||
| >500/μL | 10.8 (9-18) | 12.0 (10-15) | 0.18 |
| >1000/μL | 12.1 (10-18) | 17.8 (10-36) | 0.03 |
| >1500/μL | 12.6 (10-18) | 19.8 (12-36) | 0.01 |
| Platelet recovery | |||
| Days to PLTS | |||
| >20 000/μL | 24.0 (9-67) | 32.0 (15-85) | 0.38 |
| >50 000/μL | 29.3 (14-49) | 34.4 (27-43) | 0.40 |
| Clinical outcomes | |||
| Febrile days | |||
| Days 2 to 10 | 4.1 (0-6) | 6.3 (5-8) | 0.01 |
| Start of regimen to day 1 | 0.2 (0-2) | 0.5 (0-4) | 0.47 |
| Days IV antibiotics | |||
| Day 2 to neutrophil engraftment5-151 | 7.3 (0-11) | 10.5 (8-13) | 0.01 |
| Start of regimen to day 1 | 0.5 (0-3) | 1.0 (0-4) | 0.40 |
| Days amphotericin B | 0 (0-0) | 1.3 (0-5) | 0.02 |
| Platelet transfusions | |||
| Day 2 to platelet engraftment5-152 | 3.4 (0-10) | 7.6 (1-18) | 0.05 |
| Start of regimen to day +1 | 0 | 0 | — |
| Days 2 to 10 | 2.1 (0-5) | 2.6 (1-7) | 0.46 |